keyword
MENU ▼
Read by QxMD icon Read
search

classical hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/28088309/-new-therapy-outlooks-in-hodgkin-lymphoma
#1
REVIEW
Cédric Rossi, René-Olivier Casasnovas
Classical Hodgkin lymphoma (HL) is a curable disease in 80% of advanced and 90% of localized stages. An improvement of the HL curability is still possible with the emergence of first-line therapy with a better balance between efficacy and toxicity and early identification patients with high risk of failure requiring specific treatment. 18FDG PET-CT gained a major role in the baseline staging and response assessment to HL treatment. The prognostic value of early PET-CT allowed to develop PET-CT guided therapies able to optimize the balance between efficacy and toxicity including the modulation of the chemotherapy intensity or the omission of radiotherapy for some localized diseases...
January 11, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28068241/chemotherapy-response-assessment-by-fdg-pet-ct-in-early-stage-classical-hodgkin-lymphoma-moving-beyond-the-five-point-deauville-score
#2
Sarah A Milgrom, Wenli Dong, Mani Akhtari, Grace L Smith, Chelsea C Pinnix, Osama Mawlawi, Eric Rohren, Naveen Garg, Hubert Chuang, Zeinab Abou Yehia, Jay P Reddy, Jillian R Gunther, Joseph D Khoury, Tina Suki, Eleanor M Osborne, Yasuhiro Oki, Michelle Fanale, Bouthaina S Dabaja
PURPOSE: In early-stage classical Hodgkin lymphoma, fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) scans are performed routinely after chemotherapy, and the 5-point Deauville score is used to report the disease response. We hypothesized that other PET-CT parameters, considered in combination with Deauville score, would improve risk stratification. METHODS AND MATERIALS: Patients treated for stage I to II Hodgkin lymphoma from 2003 to 2013, who were aged ≥18 years and had analyzable PET-CT scans performed before and after chemotherapy, were eligible...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28042455/differences-in-outcome-of-patients-with-syncytial-variant-hodgkin-lymphoma-compared-with-typical-nodular-sclerosis-hodgkin-lymphoma
#3
Tarsheen Sethi, Van Nguyen, Shaoying Li, David Morgan, John Greer, Nishitha Reddy
BACKGROUND: Nodular sclerosis Hodgkin lymphoma (NS-HL) is the most common subtype of HL and usually has a good prognosis. A variant of NS, the syncytial variant (SV) has well-established histopathologic features but little is known about its clinical behavior. Small case series have suggested that SV patients present with advanced disease and have a comparatively aggressive course. The objective of this study was to determine the clinical characteristics and outcome of SV patients. METHODS: A total of 167 adult patients with NS-HL including 43 patients with SV and 124 patients with typical NS (t-NS) were included in our analysis following institutional review board (IRB) approval...
January 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/28038705/cyclin-d1-expression-and-polysomy-in-lymphocyte-predominant-cells-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#4
Benjamin B Cho, Sarah M Kelting, Alejandro A Gru, Robin D LeGallo, Patcharin Pramoonjago, Teresa A Goldin, Christopher T Heitz, Nadine S Aguilera
Cyclin D1 protein expression in lymphocytes is classically associated with mantle cell lymphoma. Although increasingly recognized in other lymphoproliferative disorders, cyclin D1 expression and CCND1 gene abnormalities have not been well studied in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Using a double stain for CD20/cyclin D1, we quantified cyclin D1 expression in 10 cases of NLPHL and correlated those findings with SOX11 expression, CCND1 gene abnormalities, and clinical data. For comparison, we examined 5 cases of T cell-/histiocyte-rich large B-cell lymphoma (THRLBCL)...
February 2017: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/28035374/activation-of-oncogenic-pathways-in-classical-hodgkin-lymphoma-by-decitabine-a-rationale-for-combination-with-small-molecular-weight-inhibitors
#5
Tatjana Maria Swerev, Thomas Wirth, Alexey Ushmorov
DNA methylation is an epigenetic control mechanism that contributes to the specific phenotype and to the oncogenic program of virtually all tumor entities. Although efficacy of demethylating agents in classical Hodgkin lymphoma (cHL) was not specifically tested, a case of regression of relapsed metastatic cHL was described as a fortunate side‑effect of the demethylating agent 5‑azacytidine in a patient with myelodysplastic syndrome. We investigated molecular mechanisms of decitabine (5‑Aza‑dC) antitumor activity in cHL using gene expression profiling followed by gene set enrichment analysis...
December 30, 2016: International Journal of Oncology
https://www.readbyqxmd.com/read/28013563/pax-5-positivity-in-anaplastic-lymphoma-kinase-negative-anaplastic-large-cell-lymphoma
#6
Indu Arun, Paromita Roy, Neeraj Arora, Saurabh Jayant Bhave, Reena Nair, Mammen Chandy
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a subtype of T-cell lymphomas that may mimic several other malignancies morphologically. With the help of immunohistochemistry, most cases of ALCL can be diagnosed on the basis of expression of T-cell lineage associated antigens. However, aberrations in the expression of immunohistochemical markers pose diagnostic challenges. The morphological and immunophenotypic features of ALCL show considerable overlap with classical Hodgkin lymphoma (CHL), which is a B-cell lymphoma...
December 1, 2016: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28010897/brentuximab-vedotin-for-treatment-of-non-hodgkin-lymphomas-a-systematic-review
#7
REVIEW
Garrett K Berger, Ali McBride, Stephanie Lawson, Kelsey Royball, Seongseok Yun, Kevin Gee, Irbaz Bin Riaz, Ahlam A Saleh, Soham Puvvada, Faiz Anwer
BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD)...
January 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27998726/characterization-and-purification-of-neoplastic-cells-of-nodular-lymphocyte-predominant-hodgkin-lymphoma-from-lymph-nodes-by-flow-cytometry-and-flow-cytometric-cell-sorting
#8
Jonathan R Fromm, Anju Thomas, Brent L Wood
We report the flow cytometric (FC) identification and characterization of lymphocyte predominant (LP) cells from lymph nodes involved by nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). First, we immunophenotyped the NLPHL cell line (DEV) confirming a germinal center immunophenotype, lack of expression of CD32 and CD58, and expression of CD54. Nineteen of 26 lymph nodes involved by NLPHL demonstrated a population with an LP immunophenotype (73%), which included expression of germinal center markers (CD75/Bcl-6-positive, CD32-weak/negative without CD10), a B-cell immunophenotype (CD19/CD20/CD40(+)), IgD and/or IgM expression (67%), and lack of programmed death-ligand 1/ligand 2...
December 17, 2016: American Journal of Pathology
https://www.readbyqxmd.com/read/27998299/rituximab-etoposide-methylprednisolone-high-dose-cytarabine-and-cisplatin-in-the-treatment-of-secondary-hemophagocytic-lymphohistiocytosis-with-classical-hodgkin-lymphoma-a-case-report-and-review-of-the-literature
#9
Steve Hu, Pranshu Bansal, David Lynch, Cristhiam Mauricio Rojas Hernandez, Zoneddy Dayao
BACKGROUND: Hemophagocytic lymphohistiocytosis is becoming an increasingly recognized disorder in adults. Classical Hodgkin lymphoma is a relatively uncommon etiology of hemophagocytic lymphohistiocytosis and may complicate treatment options. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin are discussed here as a treatment regimen. CASE PRESENTATION: A 66-year-old Hispanic man previously in good health presented with a 1-month history of recurrent fevers, chills, and night sweats and a 3-week history of new onset jaundice...
December 20, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27991731/novel-treatment-concepts-in-hodgkin-lymphoma
#10
REVIEW
I Glimelius, A Diepstra
Treatment of classical Hodgkin's lymphoma (HL) has been a success story, with cure of localized disease with radiotherapy in the 1930s, cure of advanced stages with combination chemotherapy with/without radiotherapy in the mid-1960s and continuous improvements since then. Nonetheless, at present approximately 2% of patients with classical HL are primarily refractory to conventional therapy with only 50% becoming long-term survivors. Another 13% of patients relapse, with only 60% being alive 10 years postrecurrence (as exemplified in this review in a Swedish cohort of 18- to 65-year-old patients diagnosed during the period 1992-2009)...
December 19, 2016: Journal of Internal Medicine
https://www.readbyqxmd.com/read/27984652/a-multi-institutional-analysis-of-peritransplantation-radiotherapy-in-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-stem-cell-transplantation
#11
Sarah A Milgrom, Shekeab Jauhari, John P Plastaras, Yago Nieto, Bouthaina S Dabaja, Chelsea C Pinnix, Grace L Smith, Pamela K Allen, J Nicholas Lukens, Amit Maity, Yasuhiro Oki, Michelle A Fanale, Sunita D Nasta
BACKGROUND: No consensus exists regarding the use of radiotherapy (RT) in conjunction with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with relapsed/refractory classical Hodgkin lymphoma (HL). The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers. METHODS: Eligible patients underwent HDC/ASCT from 2006 through 2015 using the combination of either carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, BCNU, and etoposide (CBV)...
December 16, 2016: Cancer
https://www.readbyqxmd.com/read/27972422/the-frequency-of-relapsed-or-refractory-disease-after-autologous-stem-cell-transplantation-in-classical-hodgkin-lymphoma-a-systematic-review
#12
S M Szabo, S Roop, A Juarez Garcia, Hirji
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27968935/cutaneous-lymphoma-kids-are-not-just-little-people
#13
Katalin Ferenczi, Hanspaul S Makkar
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that predominantly affect older patients. Onset of cutaneous lymphoma in childhood is rare, but it can present as early as the first decade of life. In both adults and children, the diagnosis of cutaneous lymphoma can be challenging because inflammatory dermatoses can mimic CTCL both clinically and histologically. The clinicopathologic manifestations can be similar in adults and younger individuals; however, differences in the prevalence of certain CTCL variants among age groups exist...
November 2016: Clinics in Dermatology
https://www.readbyqxmd.com/read/27960645/combined-therapy-in-children-and-adolescents-with-classical-hodgkin-s-lymphoma-a-report-from-the-sfce-on-mdh-03-national-guidelines
#14
E Seror, J Donadieu, H Pacquement, S Abbou, A Lambilliotte, M Schell, C Curtillet, V Gandemer, M Pasquet, N Aladjidi, P Lutz, C Schmitt, A Deville, O Minckes, J P Vanier, C Armari-Alla, C Thomas, S Gorde-Grosjean, F Millot, P Blouin, N Garnier, C Coze, C Devoldere, Y Reguerre, S Helfre, L Claude, J Clavel, O Oberlin, J Landman-Parker, T Leblanc
Hodgkin's lymphoma (HL) in children and adolescents is highly curable, but children are at risk of long-term toxicity. The MDH-03 guidelines were established in order to decrease the burden of treatment in good-responder patients, and this report should be considered a step toward further optimization of treatment within large collaborative trials. We report the therapy and long-term outcomes of 417 children and adolescents treated according to the national guidelines, which were applied between 2003 and 2007 in France...
October 2016: Pediatric Hematology and Oncology
https://www.readbyqxmd.com/read/27927047/diagnostic-prognostic-and-therapeutic-role-of-cd30-in-lymphoma
#15
John Matthew R Pierce, Amitkumar Mehta
CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Development of Brentuximab vedotin (BV), an antibody-drug conjugate directed to CD30, has been an important advance in lymphoma treatment...
January 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/27920704/autoimmune-hemolytic-anemia-as-a-complication-of-nivolumab-therapy
#16
Amruth R Palla, Devin Kennedy, Hossain Mosharraf, Donald Doll
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic protocols for first-, second-, or third-line agents for these metastatic cancers. Immune checkpoint inhibitor nivolumab is currently FDA approved for the treatment of patients with metastatic malignant melanoma [Redman et al...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27895166/t-cell-rich-lymphoid-infiltrates-with-large-b-cells-a-review-of-key-entities-and-diagnostic-approach
#17
REVIEW
Chee Leong Cheng, Simon O'Connor
Accurate diagnostic interpretation of a lymphoid population composed predominantly of small T cells, together with smaller numbers of large B cells, with or without a nodular architecture, is a common problem faced by the histopathologist. The differential diagnosis of this histological pattern is wide, ranging from reactive conditions such as drug reactions and viral infections, through borderline entities such as immunodeficiency-related lymphoproliferative disorders to lymphomas. The latter includes entities where the large B cells are primarily neoplastic (classical and nodular lymphocyte-predominant Hodgkin lymphomas and T cell/histiocyte-rich large B cell lymphoma) as well as T cell lymphomas such as angioimmunoblastic T cell lymphoma where the large B cells represent an epiphenomenon and may or may not be neoplastic...
November 28, 2016: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27888879/gray-zone-lymphoma-current-diagnosis-and-treatment-options
#18
REVIEW
Monika Pilichowska, Athena Kritharis, Andrew M Evens
The morphology of gray zone lymphoma (GZL) is variable with tumor cells spanning the spectrum of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. The immunophenotype is frequently discordant. Clinically, the initial case descriptions of GZL were primarily with mediastinal presentation; however, a nonmediastinal (systemic) clinical subtype is now recognized. Patients with GZL have high relapse rates. Recommended treatment of GZL is with a DLBCL-directed regimen with consideration for consolidative radiotherapy for bulk disease...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888658/a-case-of-composite-classical-and-nodular-lymphocyte-predominant-hodgkin-lymphoma-with-progression-to-diffuse-large-b-cell-non-hodgkin-lymphoma-diagnostic-difficulty-in-fine-needle-aspiration-cytology
#19
Dilip K Das, Zafar A Sheikh, Mariam H Al-Shama'a, Bency John, Abdulla M S Alawi, Thamradeen A Junaid
A small percentage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL) progresses to diffuse large B-cell lymphoma (DLBCL). There have also been rare reports of gray zone lymphoma with features intermediate between classical Hodgkin lymphoma (CHL) and DLBCL. We report a very rare case of composite lymphoma (CHL and NLPHL) progressing to DLBCL, and highlight the diagnostic difficulty faced during its fine-needle aspiration (FNA) cytology diagnosis. A 65-year-old woman presented with a right axillary swelling which was subjected to FNA cytology...
November 26, 2016: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/27887763/composite-lymphoma-with-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma-components-a-case-report-and-review-of-the-literature
#20
Gaurav Goyal, Austin Huy Nguyen, Kayla Kendric, Gabriel C Caponetti
Composite lymphoma (CL) is an infrequently diagnosed entity in which two or more distinct types of lymphomas occur synchronously in the same organ or anatomical site. Most commonly, CLs are composed of two non-Hodgkin B-cell lymphomas. We present a case of a composite lymphoma with diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS) and classical Hodgkin lymphoma (CHL) components involving the terminal ileum, colon and pericolic lymph nodes. Immunohistochemical evaluation for determination of cell of origin of the DLBCL-NOS component indicated a germinal center B-cell subtype...
December 2016: Pathology, Research and Practice
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"